Search research articles
Contact Us
Filters
Showing results (341-350 of 367) with videos related to
Page
of 37
Sort By:
Investigational New Drugs
|
April 10, 2013
Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients
Douglas A Rubinson, Howard S Hochster, David P Ryan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 25, 2010
Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma
M Bendandi, S Marillonnet, R Kandzia, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to <i>KRAS</i> mutational status
E B Faber, Y Baca, J Xiu, et al.
The Pharmacogenomics Journal
|
February 12, 2014
Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients
F Loupakis, C Antoniotti, C Cremolini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 17, 2018
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study
E Van Cutsem, T Yoshino, H J Lenz, et al.
The Pharmacogenomics Journal
|
June 1, 2016
Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer
Y Sunakawa, S Cao, N B Volz, et al.
ESMO Open
|
June 10, 2022
Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11)
Y Sunakawa, H Satake, J Usher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2015
Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials
Y Sunakawa, S Stintzing, S Cao, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 28, 2026
Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer: An analysis of 18,041 patients in the ARCAD CRC database
Anna Dorothea Wagner, Morteza Raeisi, Manel Rakez, et al.
The Pharmacogenomics Journal
|
April 12, 2017
Prognostic impact of FOXF1 polymorphisms in gastric cancer patients
S Matsusaka, A H Wu, S Cao, et al.
Page
of 37
Search research articles
Search
Showing results (341-350 of 367) with videos related to
Sort By:
Page
of 37
Investigational New Drugs
|
April 10, 2013
Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients
Douglas A Rubinson, Howard S Hochster, David P Ryan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 25, 2010
Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma
M Bendandi, S Marillonnet, R Kandzia, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to <i>KRAS</i> mutational status
E B Faber, Y Baca, J Xiu, et al.
The Pharmacogenomics Journal
|
February 12, 2014
Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients
F Loupakis, C Antoniotti, C Cremolini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 17, 2018
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study
E Van Cutsem, T Yoshino, H J Lenz, et al.
The Pharmacogenomics Journal
|
June 1, 2016
Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer
Y Sunakawa, S Cao, N B Volz, et al.
ESMO Open
|
June 10, 2022
Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11)
Y Sunakawa, H Satake, J Usher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2015
Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials
Y Sunakawa, S Stintzing, S Cao, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 28, 2026
Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer: An analysis of 18,041 patients in the ARCAD CRC database
Anna Dorothea Wagner, Morteza Raeisi, Manel Rakez, et al.
The Pharmacogenomics Journal
|
April 12, 2017
Prognostic impact of FOXF1 polymorphisms in gastric cancer patients
S Matsusaka, A H Wu, S Cao, et al.
Page
of 37